Pharmaceuticals, Biotechnology and Life Sciences
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CETPARIS and CAMBRIDGE, Mass.,…
Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of…
– Continued favorable safety profile for DYNE-251 – – DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned…
– The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα…
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients…
ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) — The attached notifications relate to annual equity incentive awards granted to members…
Company Expands into Cannabis Business Management and Functional Mushroom Markets to Drive Growth and Profitability LOS ANGELES, CA, March 13,…
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD)…
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for…